SEC Comment Letter 0000000000-24-012541 to Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Date: Nov. 12, 2024 · CIK: 0001827506 · Accession: 0000000000-24-012541
AI Filing Summary & Sentiment
File numbers found in text: 333-283078
Letter
November 12, 2024 Sandeep Kulkarni, MD President and Chief Executive Officer Tourmaline Bio, Inc. 27 West 24th Street, Suite 702 New York, NY 10010 Re:Tourmaline Bio, Inc. Registration Statement on Form S-3 Filed November 7, 2024 File No. 333-283078 Dear Sandeep Kulkarni MD: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Katherine Denby, Esq.
Show Raw Text
November 12, 2024
Sandeep Kulkarni, MD
President and Chief Executive Officer
Tourmaline Bio, Inc.
27 West 24th Street, Suite 702
New York, NY 10010
Re:Tourmaline Bio, Inc.
Registration Statement on Form S-3
Filed November 7, 2024
File No. 333-283078
Dear Sandeep Kulkarni MD:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Katherine Denby, Esq.